A small study tested the efficacy of low-dose IL-2 therapy in combination with the anti-IL-6 receptor antibody tocilizumab in RA patients [107] as IL-6 is known to increase the Th17:Treg ratio and is a driver of this disease (Reviewed by [115]). The gene discussed is IL2; the disease is rheumatoid arthritis.